Merck.com
merck.com
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improve lives.
News
Merck and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study...
At the Interim Analysis, 7.3 Percent of Patients Who Received Molnupiravir Were Hospitalized Through Day 29, Compared With 14.1 Percent of Placebo-Treated Patients Who were Hospitalized or Died Merck Plans to Seek Emergency Use Authorization in the U.S. a
Read more
Report
Merck Statement on Ivermectin use During the COVID-19 Pandemic
KENILWORTH, N.J., Feb. 4, 2021 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today affirmed its position regarding use of ivermectin during the COVID-19 pandemic. Company scientists continue to carefully examine the findings of a
Read more
Report
Report
TRANSPARENCY AND PRIVACY
A key element in our approach to privacy at our company is our commitment to transparency in our privacy program. We aim to achieve this by providing clear and understandable notices of our privacy practices that enable our stakeholders to make meaningful
Read more
Report